Concepedia

Abhijit Ramachandran

AR

Statistics

Publications

13

Citations

1.2K

H-Index

13

Active since

2009

Affiliations

Arog Pharmaceuticals (United States)(Current)

The University of Texas MD Anderson Cancer Center

Sidney Kimmel Comprehensive Cancer Center

The University of Texas Southwestern Medical Center

Johns Hopkins University

Abhijit Ramachandran is an author at Arog Pharmaceuticals (United States) specializing in molecular oncology, medicine, and oncology.

Publications per year

2009–2017

13

Publications

13

Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants

Allison Galanis, Hayley Ma, Trivikram Rajkhowa et al. · Blood · 2013 · 250 citations

, , +9

Crenolanib Inhibits the Drug-Resistant PDGFRA D842V Mutation Associated with Imatinib-Resistant Gastrointestinal Stromal Tumors

Michael C. Heinrich, Diana Griffith, Arin McKinley et al. · Clinical Cancer Research · 2012 · 220 citations

, , +14

Crenolanib is active against models of drug-resistant FLT3-ITD−positive acute myeloid leukemia

Eric I. Zimmerman, David C. Turner, Jassada Buaboonnam et al. · Blood · 2013 · 183 citations · Full text

, , +8

Results of a Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients (Pts) with Activating FLT3 Mutations

Jasleen K. Randhawa, Hagop M. Kantarjian, Gautam Borthakur et al. · Blood · 2014 · 115 citations

, , +13

Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML.

Jörge E. Cortes, Hagop M. Kantarjian, Tapan M. Kadia et al. · Journal of Clinical Oncology · 2016 · 101 citations

, , +14

1–5 of 13